Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 14Genitourinary 4Endocrine 4NET 2Gastrointestinal 2CNS 2Sarcoma 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Neuroendocrine Tumors 169Carcinoid Tumor 27Carcinoma, Neuroendocrine 22Neoplasms 16Gastro-enteropancreatic neuroendocrine tumor 16Adenoma, Islet Cell 15Pancreatic Neoplasms 12Neoplasm Metastasis 10Pheochromocytoma 8Paraganglioma 8Sarcoma 7Colorectal Neoplasms 7Carcinoma 7Neuroectodermal Tumors, Primitive 6Neuroblastoma 6Gastrointestinal Neoplasms 6Vipoma 5Somatostatinoma 5Gastrinoma 5Cholangiocarcinoma 5Carcinoma, Islet Cell 5Breast Neoplasms 5Small Cell Lung Carcinoma 4Serotonin Syndrome 4Digestive System Neoplasms 4Anus Neoplasms 4Thyroid Neoplasms 3Salivary Gland Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3

Interventions

taxane 1liposomal doxorubicin 1Vinorelbine 1RRx-001 1Pemetrexed 1Paclitaxel 1Irinotecan 1Gemcitabine 1Etoposide 1Cisplatin 1Carboplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Small Cell × NET × Clear all
NCT05500391 2026-03-18

SUR-CAN

Centre Oscar Lambret

Phase 2 Recruiting
88 enrolled
CNSEndocrineGastrointestinalNETSarcoma

Carcinosarcoma, Glioma, Seminoma, Adenocarcinoma, Clear Cell, Carcinoma, Small Cell, Sex Cord-Gonadal Stromal Tumors, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡